



On the trail of the obesity paradox

Nadine Gladow, Ulrich Hofmann

Department of Internal Medicine I, University Hospital Wuerzburg, Wuerzburg, Germany

Correspondence to: Ulrich Hofmann. Department of Internal Medicine I, University Hospital Wuerzburg, Wuerzburg, Germany. Email: hofmann_u2@ukw.de.

Comment on: Yang J, Mai B, Su Y, *et al.* Twelve-week high-fat diet for improving adverse ventricular remodeling post-myocardial infarction by alleviating local inflammation. *Ann Transl Med* 2022;10:1089.

Submitted Oct 08, 2022. Accepted for publication Oct 19, 2022.

doi: 10.21037/atm-2022-40

View this article at: <https://dx.doi.org/10.21037/atm-2022-40>

The obesity paradox refers to the phenomenon that overweight or obesity in patients with diseases, for which obesity and its metabolic sequelae constitute risk factors, may be protective and hence associated with decreased mortality. Gruberg *et al.* (1) observed that overall mortality was significantly higher in patients with coronary artery disease after percutaneous coronary intervention and normal body mass index (BMI) compared to overweight subjects. Since then, a number of studies, often encompassed by the term “reverse epidemiology”, found that obesity or overweight, mostly defined by BMI, were associated with improved survival in chronic heart failure (CHF) (2), after acute myocardial infarction (3), and after cardiac surgery (4).

Noteworthy, significant heterogeneity was found across studies supporting the presence of the obesity paradox (5) and existence remains a point of debate, because it is mostly observed when BMI is used to define obesity. Inherent limitations of BMI as an index of adiposity, as well as methodological biases and the presence of confounding factors, may account for the observed discrepant findings of clinical studies. Importantly, BMI does not take into account body composition phenotypes and metabolic variables. Nevertheless, it is clinically relevant to understand if and how obesity-related mechanism beneficially modulate pathophysiological processes leading to heart failure.

A high body fat ratio and certain fat distribution pattern, which are prevalent in subjects with high BMI, are correlated with a pro-inflammatory status. Systemic chronic low-grade inflammation is mechanistically linked to obesity related disease, e.g., atherosclerosis. Metabolic factors associated with obesity, e.g., hyperglycemia and hypercholesterinemia, elicit hematopoietic rewiring and epigenetic remodeling in bone marrow precursors

(6-8). Moreover, the onset of obesity is characterized by accumulation of proinflammatory myeloid cells in many tissues (9). Clinically, obesity is associated with higher leukocyte blood counts and other markers of systemic inflammation which can already be observed in children (10).

Inflammation is a key component of both adverse myocardial remodeling after myocardial infarction and its systemic sequelae (11). Accordingly, several clinical studies revealed that the prognosis after myocardial infarction negatively correlates with measures of inflammation, e.g., blood monocyte levels predict on the outcome (12,13). The early healing phase after myocardial infarction is considered as critical determinant of future adverse remodeling and heart failure. Although the major source of blood myeloid cells under steady-state conditions is the bone marrow, monocytes immediately influx the heart from the spleen after myocardial infarction and the spleen becomes an organ of myelopoiesis (14). An extensive body of experimental evidence accumulated over the last years demonstrating a causative role of excess myelopoiesis, monocyte-derived macrophages and impaired healing (15,16). Therefore, one might hypothesize that obesity has adverse effects on myocardial healing and promotes adverse remodeling which would be seemingly contradictory to the obesity paradox.

Yang *et al.* (17) now report that feeding mice a high-fat diet (HFD) for 8 weeks provoked mild obesity not causing cardiac pathology. Mice subjected to such HFD developed less pronounced ventricular remodeling and systolic dysfunction 28 days post myocardial infarction. The number of total leukocytes within the heart was significantly lower in HFD mice at 7 days after myocardial infarction whereas the number of regulatory CD4⁺ T cells was increased. Enhanced regulatory T cell recruitment promotes anti-

inflammatory macrophage differentiation and myocardial healing (18). Hence, the reported immunological findings could account for the overall protective effect of HFD after myocardial infarction and might even explain why obesity is protective in various chronic disease states. However, there are other contradictory findings in studies using HFD feeding protocols in experimental models of myocardial infarction. Thakker *et al.* reported enhanced left ventricular remodeling after myocardial ischemia-reperfusion in obese mice (19). Moreover, Mouton *et al.* described lower survival rates in obese male mice but less left ventricular dilation in surviving animals after myocardial infarction (20). The discrepant findings might partially rely on differences in the animal models used (ischemia-reperfusion *vs.* permanent coronary ligation, sex, strain, and metabolic characteristics). Therefore, before further investing in mouse studies, an in depth clinical characterization of patients after ST-elevation myocardial infarction (STEMI) allowing to correlate components of the metabolic syndrome and inflammation with infarct size and parameters describing myocardial healing and remodeling would be highly informative. This could be optimally achieved by a longitudinal characterization of a cohort of STEMI patients by cardiac magnetic resonance imaging combined by a thorough clinical phenotyping of the patients including parameters reflecting inflammation.

Acknowledgments

Funding: UH received funding for a related research project by the German Research Foundation (Project Number 391580509).

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, *Annals of Translational Medicine*. The article did not undergo external peer review.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at <https://atm.amegroups.com/article/view/10.21037/atm-2022-40/coif>). UH reports research support from the German Research Foundation (Project Number 391580509), consulting Fees from Astra Zeneca, Boehringer Ingelheim, Novartis, and payment for Advisory Boards from Boehringer. The other author has no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all

aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Gruberg L, Weissman NJ, Waksman R, et al. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? *J Am Coll Cardiol* 2002;39:578-84.
2. Kalantar-Zadeh K, Block G, Horwich T, et al. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. *J Am Coll Cardiol* 2004;43:1439-44.
3. Niedziela J, Hudzik B, Niedziela N, et al. The obesity paradox in acute coronary syndrome: a meta-analysis. *Eur J Epidemiol* 2014;29:801-12.
4. Takagi H, Umemoto T; ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. Overweight, but not obesity, paradox on mortality following coronary artery bypass grafting. *J Cardiol* 2016;68:215-21.
5. Antonopoulos AS, Oikonomou EK, Antoniadou C, et al. From the BMI paradox to the obesity paradox: the obesity-mortality association in coronary heart disease. *Obes Rev* 2016;17:989-1000.
6. Nagareddy PR, Murphy AJ, Stirzaker RA, et al. Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. *Cell Metab* 2013;17:695-708.
7. Singer K, DelProposto J, Morris DL, et al. Diet-induced obesity promotes myelopoiesis in hematopoietic stem cells. *Mol Metab* 2014;3:664-75.
8. Trottier MD, Naaz A, Li Y, et al. Enhancement of hematopoiesis and lymphopoiesis in diet-induced obese mice. *Proc Natl Acad Sci U S A* 2012;109:7622-9.
9. Bowers E, Singer K. Obesity-induced inflammation: The impact of the hematopoietic stem cell niche. *JCI Insight* 2021;6:145295.

10. Singer K, Eng DS, Lumeng CN, et al. The relationship between body fat mass percentiles and inflammation in children. *Obesity (Silver Spring)* 2014;22:1332-6.
11. Hofmann U, Frantz S. Immunity strikes: heart failure as a systemic disease. *Eur Heart J* 2014;35:341-3.
12. Hong YJ, Jeong MH, Ahn Y, et al. Relationship between peripheral monocytois and nonrecovery of left ventricular function in patients with left ventricular dysfunction complicated with acute myocardial infarction. *Circ J* 2007;71:1219-24.
13. Maekawa Y, Anzai T, Yoshikawa T, et al. Prognostic significance of peripheral monocytois after reperfused acute myocardial infarction:a possible role for left ventricular remodeling. *J Am Coll Cardiol* 2002;39:241-6.
14. Leuschner F, Rauch PJ, Ueno T, et al. Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis. *J Exp Med* 2012;209:123-37.
15. Shinagawa H, Frantz S. Cellular immunity and cardiac remodeling after myocardial infarction: role of neutrophils, monocytes, and macrophages. *Curr Heart Fail Rep* 2015;12:247-54.
16. Frantz S, Nahrendorf M. Cardiac macrophages and their role in ischaemic heart disease. *Cardiovasc Res* 2014;102:240-8.
17. Yang J, Mai B, Su Y, et al. Twelve-week high-fat diet for improving adverse ventricular remodeling post-myocardial infarction by alleviating local inflammation. *Ann Transl Med* 2022;10:1089.
18. Weirather J, Hofmann UD, Beyersdorf N, et al. Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation. *Circ Res* 2014;115:55-67.
19. Thakker GD, Frangogiannis NG, Bujak M, et al. Effects of diet-induced obesity on inflammation and remodeling after myocardial infarction. *Am J Physiol Heart Circ Physiol* 2006;291:H2504-14.
20. Mouton AJ, Flynn ER, Moak SP, et al. Interaction of Obesity and Hypertension on Cardiac Metabolic Remodeling and Survival Following Myocardial Infarction. *J Am Heart Assoc* 2021;10:e018212.

Cite this article as: Gladow N, Hofmann U. On the trail of the obesity paradox. *Ann Transl Med* 2022;10(20):1081. doi: 10.21037/atm-2022-40